EGFR and lung carcinoma: A randomized phase 2 study design comparing osimertinib monotherapy and combined therapy with bevacizumab for patients with lung cancer harboring sensitizing EGFR mutations with malignant pleural or pericardial effusion may eliminate this problem; however, on the basis of the results of this study and the WJOG9717L23 trial, such a trial may not be viable.